Lilly presented Phase I data from the type II JAK inhibitor, showing good efficacy and safety.

ASCO 2026 plenary data establishes daraxonrasib as the new second-line standard of care for advanced pancreatic tumors.

Novel gedatolisib is currently under review at FDA for wild-type patients ...

A high-throughput cytometry workflow consolidates marker expression, proliferation, and cytokine release into a single assay ...

Weekly subcutaneous injections of the novel B-cell inhibitor obexelimab significantly reduces disease flares and lowers toxic ...

Preclinical studies suggest that this combination may lead to complete and durable responses across a variety of solid tumor types.

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar ...

Kerry Rogers, MD, examines the underemphasized BTK inhibitor adverse effects that quietly erode patient quality of life—and ...

When researchers use an inhibitor to block a kinase’s activity, they generally expect to see less of the downstream effects of that kinase. So when neuroscientists observed the opposite using a new ...

Share on Pinterest Scientists are studying treatments to reduce inflammation in Crohn’s disease and ulcerative colitis. Tom Werner/Getty Images Inflammatory bowel disease is a term that includes Crohn ...